In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 351 to 375 of 419

TitleTypeExpected publication date
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)Medical technologies guidanceTBC
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Technology appraisal guidance
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]Technology appraisal guidanceTBC
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]Technology appraisal guidanceTBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]Technology appraisal guidanceTBC
Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shockInterventional procedures guidance
Surgical mesh for ventral herniasHealth technology evaluationTBC
Surgical vessel sealing systems (MT798)Medical technologies guidanceTBC
Suspected Cancer: recognition and referral (update)NICE guideline
Suspected sepsis in pregnancy: recognition, diagnosis and early managementNICE guideline
Suspected sepsis in under 16s: recognition, diagnosis and early managementNICE guideline
Suspected sepsis: recognition, diagnosis and early managementNICE guidelineTBC
Suspected sepsis: recognition, diagnosis and early management - procalcitonin testingNICE guideline
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]Technology appraisal guidance
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413Technology appraisal guidance
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]Technology appraisal guidanceTBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Technology appraisal guidance
Tarlatamamb for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]Technology appraisal guidanceTBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401Technology appraisal guidanceTBC
Technologies to support the rapid diagnosis of endometriosis (provisional title)Health technology evaluationTBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]Technology appraisal guidance
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Technology appraisal guidanceTBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]Technology appraisal guidance
Teprotumumab for treating thyroid eye disease [ID6432]Technology appraisal guidanceTBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All